1. Home
  2. GHM vs ABUS Comparison

GHM vs ABUS Comparison

Compare GHM & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Graham Corporation

GHM

Graham Corporation

HOLD

Current Price

$98.87

Market Cap

899.3M

Sector

Industrials

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.56

Market Cap

848.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GHM
ABUS
Founded
1936
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
899.3M
848.8M
IPO Year
1994
2008

Fundamental Metrics

Financial Performance
Metric
GHM
ABUS
Price
$98.87
$4.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$73.33
$5.00
AVG Volume (30 Days)
185.1K
1.2M
Earning Date
06-08-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
164.29
55.26
EPS
0.95
0.87
Revenue
$209,896,000.00
$14,083,000.00
Revenue This Year
$14.54
N/A
Revenue Next Year
$18.23
$239.71
P/E Ratio
$106.32
$5.28
Revenue Growth
13.13
128.21
52 Week Low
$38.93
$3.04
52 Week High
$103.53
$5.10

Technical Indicators

Market Signals
Indicator
GHM
ABUS
Relative Strength Index (RSI) 56.95 57.10
Support Level $88.62 $4.16
Resistance Level $100.96 $4.60
Average True Range (ATR) 5.35 0.18
MACD -0.04 0.04
Stochastic Oscillator 69.18 67.81

Price Performance

Historical Comparison
GHM
ABUS

About GHM Graham Corporation

Graham Corporation designs and manufactures mission-critical fluid, power, heat transfer, and vacuum technologies for the defense, space, energy, and process industries. The company also services and sells spare parts for its equipment. It designs and manufactures custom-engineered vacuum, heat transfer, cryogenic pump and turbomachinery technologies.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: